Mucin1(MUC1)expressioncorrelateswithinvasionandmetastasisandpoorsurvival in some cancers. The purpose of the study was to investigate the clinical significance of MUC1 expression and the risk of tumor metastatic recurrence in patients with esophageal squamous cell cancer (ESCC) after curative resection. Atotalof108ESCCpatientswereenrolledinthisstudy.MUC1expressionwas detectedinESCCtissuesfrom70patientsbyimmunohistochemistry(IHC).The expressionofMUC1inthecanceroustissuegroupwassignificantlyhigherthan thatintheparacancerousnormaltissuegroup(65.4%:10.0%,p<0.01).MUC1 expressioncorrelatedwithpT(<0.05),pN(p<0.01)andpTNMstage(<0.01). The5-yearsurvivalrateofthepatientswas39.8%.The5-yeartumormetastatic recurrence rate of the patients was 74.1%, and it was associated with pT (p < 0.01),pN(p<0.01),pTNMstage(p<0.01)andMUC1expression(p<0.01). MultivariateanalysisconfirmedthatpNandMUC1expressionwereindependent predictive factors. In conclusion, MUC1 expression correlates with tumor metastaticrecurrenceinpostoperativeESCCpatients.
Introduction
Esophageal cancer is one of the most common malignancies in China. The major histological type is esophageal squamous cell carcinoma (ESCC). Esophagectomyhasremainedthemosteffectivemodality for ESCC patients. However, the long-term outcome is unsatisfactory, and the 5-year survival rateisonly20-30% [1] .Morethanhalfofthepostoperative patients developed recurrence within 2-3 years,and80%wouldeventuallydiefromtumorre-currence [2, 3] . To date, TNM staging is the main parameter for predicting recurrence and prognosis, eventhoughitlackssensitivityandaccuracy.Therefore, the discovery of a sensitive reliable biomarker identifying the high-risk patient with recurrence is crucialforimprovementofthesurvivalrate [4] . Recentstudieshaverevealedthatseveralgenesare involvedintheoriginandprogressionofESCC.Ithas beenreportedthatMucin1(MUC1)playsimportant rolesindevelopmentandprogressionofsomecancers [5, 6] .MUC1isastructuralmembranousboundmu-cin,expressedontheapicalsurfaceofnormalglandularepithelialcellsinnormaltissues [7] .Inneoplastic tissues,MUC1expressioncouldbeup-regulatedand couldbeexpressedontheentirecellsurface.MUC1 expression correlates with invasion, metastasis and poorprognosisinsomecancers.
However,fewreportshaveconfirmedthecorrelationbetweenMUC1expressionandclinicopatholog-icalcharacteristicsinpatientswithESCC.Thus,the presentstudywasdesignedtoinvestigatetheclinical significanceofMUC1expressionanditscorrelation with the risk of tumor metastatic recurrence in patients with ESCC after curative resection by both univariate and multivariate analysis. In the study, MUC1 expression was detected by immunohistochemistry(IHC). 
Material and methods

Patients
Immunohistochemistry
AlltheESCCspecimenswereobtainedfromthe 108 patients. Twenty corresponding normal tissue samples, which came from the 108 patients' normal esophagus (6 cm away from ESCC) randomly, were used as controls. The tissue specimens were fixed in 10% neutral buffered formalin and processed routinely. Hematoxylin and eosin (HE)-stained slides as well as immunohistochemical reactions were performed on paraffin-embedded and formalin-fixed tissue using primary antibodies against MUC1 (1 : 100 dilution; Fuzhou Maxim Inc., Fuzhou, Fujian, China) and visualized by theEnvisionSystem(Dako).MUC1waslocatedin the tumor cell cytoplasm. MUC1 protein expression is indicated by bright yellow, brown yellow or brown granules focally or diffusively distributed. The expression of MUC1 was scored as follows: 0, 1 = < 5% of cells; 2 = 5-29% of cells; 3=30-60%ofcells;4=>60%ofcells.Cancers were regarded as positive when the score was ≥ 3, accordingtopreviousreports [8, 9] .
Follow-up
In our cases, 12 patients received postoperative radiotherapyalone.Postoperativechemotherapywas givento44patientsinmorethanthreecycles(mainly 5-fluorouracilandcisplatin/carboplatin),and26pa-tientsreceivedcombinedchemoradiotherapy.Patients wereroutinelyexaminedevery3monthsduringthe first3yearsandevery6monthsthereafter.During each follow-up visit, the patient underwent a thorough physical examination, chest roentgenography, ultrasonography of the neck and abdomen, chest CT,andendoscopicexamination.Somepatientseven underwentpositronemissiontomographycombined withcomputedtomography(PET/CT)examination. Thelocationandtimeoftumorrelapsewererecorded.Patientswhodiedoftumorwereenrolledinthe prognosticanalysis. 
Statistical analysis
Correlation between MUC1 expression and tumor metastatic recurrence
The Kaplan-Meier method indicated that the 5-year survival rate of the 108 patients was 39.8% (Fig.2) .Thefirstrecurrenceexhibitinglymphnodal metastasiswasrecognizedin80patients(74.1%)in thefirst5yearsaftertheoperation (Fig.3) .Thepatientshadthefirstrecurrenceincervical,supraclavicular,mediastinal,andceliaclymphnodes(TableIII). Forty-onepatients(51.25%)developedlymphnode recurrence;24patients(30.00%)developedahematogenous recurrence and 15 patients (18.75%) had lymph node and hematogenous recurrence. In univariate analysis by the log-rank test (Table IV) latedto5-yeartumormetastaticrecurrencerate.The results of Cox regression multivariate analysis confirmedthatpNandMUC1expressionwereindepen-dentpredictivefactors(TableV).
Discussion
MUC1 expression correlated with invasion and metastasisandpoorsurvivalinsomecancers.Itwas reported that MUC1 was overexpressed in breast cancer,andwasabsentorexpressedatalowlevelin normalmammarygland.MUC1mightbeapoten-tialtargetinbreastcancerimmunotherapy [10, 11] . In gastric cancer, MUC1 was not only expressed in metastatic disease, but also found to be highly expressedinprimarytumor,indicatingthatitmightbe promoting initial spread [12, 13] . High MUC1 expressionwasalsoassociatedwithlymphnodemetastasisandvascularinvasioninliver [14] andpancreas [15] cancerandoralsquamouscellcarcinoma [16] . MUC1wasalsoassociatedwithhighergradetumors andshortermetastasis-freesurvivalinrenalcellcarcinoma [17] , thyroid cancer, and lymphomas [18] . ThesestudiesrevealedastronglinkbetweenMUC1 expressionandmetastaticprogression.
OnlyafewstudieshavereportedtheclinicopathologicalcharacteristicsofMUC1inESCCpatients,and theircorrelationremainscontroversial.Guillemet al. andpTNM.The5-yeartumormetastaticrecurrence rate of the patients with MUC1 expression in tumor issue was significantly higher than that of the patients without expression in a univariate analysis.
To eliminate the impact of mixed factors correlated withtheresultonstatisticalanalysis,Coxregression multivariate analysis was performed to determine the independent predictive factors. pN and MUC1 expression were the independent predictive factors fortumormetastaticrecurrence.Theexaminationof MUC1 expression in ESCC would become a useful markertopredicttumormetastaticrecurrence.
In conclusion, the expression of MUC1 is related to tumor invasion, lymph node metastasis and pTNM in ESCC. MUC1 expression correlates with tumormetastaticrecurrenceinESCCpatients.
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